Home » Topics » Regulatory » EMA

EMA
RSS

Lux Biosciences withdraws Luveniq MAA

Oct. 19, 2011

EMA confirms design of Intercell's planned phase II/III trial of Pseudomonas aeruginosa vaccine

Oct. 13, 2011

EMA recommends new orphan designation for 4SC-201

Oct. 13, 2011

EMA accepts MAA for IB-1001

Oct. 4, 2011

Aegerion gives update on European filing for lomitapide

Sep. 30, 2011

CHMP recommends approval of Prevanar 13 for new indication

Sep. 28, 2011

CHMP issues opinion on new indication for Avastin

Sep. 28, 2011

CHMP recommends approval of Alimta for new indication

Sep. 27, 2011

FDA approves new indication for Soliris

Sep. 27, 2011

Kombiglyze recommended for approval in E.U.

Sep. 27, 2011

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...